



A practical approach to the ESC 2022 cardio-oncology guidelines. Comments by a team of experts: cardiologists and oncologists

Authors: Przemysław Leszek, Aneta Klotzka, Stanisław Bartuś, Paweł Burchardt, Anna M Czarnecka, Monika Długosz-Danecka, Marek Gierlotka, Hanna Koseła-Paterczyk, Agata Krawczyk-Ożóg, Tomasz Kubiawski, Marcin Kurzyna, Adam Maciejczyk, Przemysław Mitkowski, Aleksander Prejbisz, Piotr Rutkowski, Ewa Sierko, Maciej Sterliński, Sebastian Szmit, Marek Szwiec, Mateusz Tajstra, Agnieszka Tycińska, Adam Witkowski, Wojciech Wojakowski, Bożena Cybulska-Stopa

Article type: Expert opinion

Received: August 1, 2023

Accepted: August 1, 2023

Early publication date: August 4, 2023

This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.

A practical approach to the ESC 2022 cardio-oncology guidelines. Comments by a team of experts: cardiologists and oncologists

Przemysław Leszek^{1*}, Aneta Klotzka^{2*}, Stanisław Bartuś³, Paweł Burchardt^{4, 5}, Anna M Czarnecka^{6, 7}, Monika Długosz-Danecka⁸, Marek Gierlotka⁹, Hanna Koseła-Paterczyk⁶, Agata Krawczyk-Ożóg³, Tomasz Kubiowski^{10, 11}, Marcin Kurzyna¹², Adam Maciejczyk^{13, 14}, Przemysław Mitkowski², Aleksander Prejbisz¹⁵, Piotr Rutkowski⁶, Ewa Sierko^{16, 17}, Maciej Sterliński¹⁸, Sebastian Szmit^{19, 20}, Marek Szwiec^{21, 22}, Mateusz Tajstra²³, Agnieszka Tycińska²⁴, Adam Witkowski²⁵, Wojciech Wojakowski²⁶, Bożena Cybulska-Stopa²⁷

¹Department of Heart Failure and Transplantology, Department of Mechanical Circulatory Support and Transplant, National Institute of Cardiology, Warszawa, Poland

²1st Department of Cardiology, Poznan University of Medical Sciences, Poznań, Poland

³2nd Department of Cardiology, Jagiellonian University Medical College, Kraków, Poland

⁴Department of Hypertension, Angiology, and Internal Medicine, Poznan University of Medical Sciences, Poznań, Poland

⁵Department of Cardiology, J Struś Hospital, Poznań, Poland

⁶Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warszawa, Poland

⁷Department of Experimental Pharmacology, Mossakowski Medical Research Center, Polish Academy of Sciences, Warszawa, Poland

⁸Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland

⁹Department of Cardiology, University Hospital, Institute of Medical Sciences, University of Opole, Opole, Poland

¹⁰University of Warmia and Mazury in Olsztyn, Olsztyn, Poland

¹¹Chemotherapy Department, Grochowski Hospital in Warsaw, Warszawa, Poland

¹²Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology Center of Postgraduate Medical Education in EHC Otwock, ERN-Lung Member, Otwock, Poland

¹³Department of Radiotherapy, Lower Silesian Center of Oncology, Katowice, Poland

¹⁴Department of Oncology, Wrocław Medical University, Wrocław, Poland

¹⁵Department of Epidemiology, Cardiovascular Prevention and Health Promotion, National Institute of Cardiology, Warszawa, Poland

¹⁶Department of Radiotherapy I, Maria Skłodowska-Curie Białystok Oncology Center, Białystok, Poland

¹⁷Department of Oncology, Medical University of Białystok, Białystok, Poland

¹⁸National Institute of Cardiology, Warszawa, Poland

¹⁹Department of Cardio-Oncology, Center of Postgraduate Medical Education, Institute of Hematology and Transfusion Medicine, Warszawa, Poland

²⁰Clinic of Oncological Diagnostics and Cardio-Oncology, Maria Skłodowska-Curie National Research Institute of Oncology, Warszawa, Poland

²¹Department of Surgery and Oncology, University of Zielona Góra, Zielona Góra, Poland

²²Clinical Department of Oncology, University Hospital of K. Marcinkowski in Zielona Góra, Zielona Góra, Poland

²³3rd Department of Cardiology, School of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland

²⁴Department of Cardiology, Medical University of Białystok, Białystok, Poland

²⁵Department of Interventional Cardiology & Angiology National Institute of Cardiology, Warszawa, Poland

²⁶Division of Cardiology and Structural Heart Diseases Medical University of Silesia, Katowice, Poland

²⁷Department of Oncology, Lower Silesian Center of Oncology, Pulmonology and Hematology, Wrocław, Poland

*Both authors equally contributed to the study

Correspondence to:

Prof. Przemysław Leszek, MD, PhD,
Department of Heart Failure and Transplantology,
Department of Mechanical Circulatory Support and Transplant,
National Institute of Cardiology,
Alpejska 42, 04–628 Warszawa, Poland,
e-mail: pleszek@ikard.pl

INTRODUCTION

The 2022 European Society of Cardiology (ESC) guidelines [1] are a comprehensive document, prepared jointly by experts in cardiology and oncology.

In the case of an oncological patient, it is necessary to individualize care in relation to the cardiological condition, the stage of the cancer and the type of potential anti-cancer therapy. Cardiac care optimisation should be undertaken before the start of oncological therapy, and continued during oncological therapy, as well as long-term after its completion [2].

The published ESC Guidelines were supplemented with a practical comments of a team of polish cardiology and oncology experts.

CARDIOVASCULAR TOXICITY RISK STRATIFICATION IN PATIENTS WITH CANCER

Cardiovascular risk stratification should be undertaken in parallel just after diagnosis of cancer. This leads to the assessment of individual cardiovascular risk, personalization and optimization of cardiac management during oncological treatment, without unnecessary delays [3].

A careful clinical history (traditional risk factors, prior history of cardiological diseases, cancer and its therapy) should be supplemented with a physical examination.

A 12-lead electrocardiogram (ECG), cardiac biomarkers for cancer therapy-related cardiovascular toxicity (CTR-CVT) (baseline assessment and follow-up) of natriuretic peptide (NP) and/or cardiac troponin (cTN) in all patients undergoing cardiotoxic therapy. The cardiovascular imaging preferably transthoracic echocardiography (TTE), possibly supplemented with 3D echocardiography or GLS (global longitudinal strain) assessment, and in case of doubt cardiac magnetic resonance (CMR) should be considered [4].

The presence of previously diagnosed cardiovascular disease requires individually selected additional tests. Pre-existing cardiovascular disease cannot automatically be a reason to withhold cancer therapy. In such patients, cardiological care is aimed at optimizing cardiovascular treatment, and thus reducing the risk before, during and after cancer treatment [5].

Practical comment

Commonly used risk scales do not include cancer patients. This is a complex multidisciplinary patient, therefore requires the decision of the Heart Team together with an dedicated oncologist — multidisciplinary team (MDT) in qualifying for invasive procedures and cardiac surgery (such as coronary artery bypass, treatment of valvular defects and others). The

common goal of multidisciplinary treatment is a complete cardio-oncological assessment, which in turn will prolong survival and improve the patient's quality of life.

PREVENTION AND MONITORING OF CARDIOVASCULAR COMPLICATIONS DURING CANCER THERAPY

Appropriate prophylaxis for CTR-CVT (including cancer therapy-related cardiac dysfunction (CTRCD)) depends on the characteristics of the particular cancer, potentially cardiotoxicity of the cancer therapy, and the patient's cardiovascular risk.

Cancer and cardiovascular disease share many common risk factors — potentially modifiable (smoking, etc.) or treatable (hypertension, etc.) [6].

Optimal treatment of the cardiovascular disease itself, avoiding adverse drug interactions is an important component of basic prevention in cardio-oncology.

In patients with at high and very high CV toxicity risk and moderate or severe CTRCD who require further anthracycline chemotherapy, liposomal anthracycline and dexrazoxane may be considered to reduce the risk of further CV toxicity [7].

Angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor antagonists (ARBs) in combination with a beta-blocker should be considered for primary prevention in high- or very high-risk patients — during the use of anthracyclines, anti-HER2 therapy and other molecularly targeted therapies that may cause CTRCD in the “off-target” mechanism [8].

Similarly, statins should be considered as part of primary prevention in adult patients at high/very high cardiovascular risk [9].

The specificity of cardiac monitoring of various cancer therapies should be based on the risk of specific cardiovascular complications associated with a given cancer treatment.

In the case of therapies with the highest risk for CTRCD (such as anthracyclines/anti-HER2), echocardiography, (possibly with GLS assessment) and biomarkers — cTn/NP) are recommended at baseline, during the use of drugs and within a year after the end of therapy.

During fluoropyrimidine therapy, it is crucial to assess the patient for complications related to ischemic heart disease. In the case of some anti-BCR-ABL therapies or hormone therapy (prostate/breast cancer), it is important to monitor the complications associated with atherosclerosis.

Blood pressure monitoring is necessary during anti-angiogenic (anti-VEGFR) therapy. Effective control of hypertension is also important during treatment with Bruton kinase inhibitors, proteasome inhibitors, MEK/RAF inhibitors [8, 9].

Practical comment

The presented document lacks information on the possibility of preventive use — secondary/primary prevention SGLT2-Inhibitors and ARNI, which may prove particularly useful in the treatment of heart failure, especially in patients experiencing CTRCD despite ACEI/ARB therapy. Also, the optimal therapeutic position for statins and beta-blockers and the optimal use of liposomal doxorubicin have not been determined.

LONG-TERM FOLLOW-UP AND CHRONIC CARDIOVASCULAR COMPLICATIONS IN CANCER SURVIVORS

Assessment of cancer patients after the completion of anti-cancer therapy includes short-term (up to 12 months) and long-term (over 12 months) management [10].

Proceedings after completion of cancer treatment — is determined by cardiac risk, type of cancer, time and intensity of anti-cancer treatment (assessed by Heart Failure Association of the ESC in collaboration with the International Cardio-Oncology Society — HFA-ICOS risk assessment).

Appropriately individualized procedures are based on the assessment of NP and/or cTn and echocardiography. Depending on the individual risk assessment, education, lifestyle modification, cardiac rehabilitation and heart failure therapy are recommended, in the group of people with left ventricular dysfunction during cancer treatment [11].

It is necessary to increase the awareness of primary care physicians also patients treated with anthracyclines, mitoxantrone (there are no data for trastuzumab) and radiotherapy, an increased risk of cardiovascular events [12].

After completion anticancer treatment cardiovascular assessment is recommended in women planning to undergo and/or in the first trimester of pregnancy.

Practical comment

The document can be complicated for primary care physicians who will play a key role in the of cancer patients in the long term care. It may seem problematic to classify patients into risk groups, especially after the end of therapy in the long term follow-up. It seems crucial to summarize and present the most important fragments of recommendations on the procedure after the end of oncological treatment in the form of a general scheme.

HEART FAILURE

Regardless of the type of treatment leading to clinically significant CTRCD, close cardiac monitoring (individualized depending on the patient's risk) over this group of patients should be carried out. Individual surveillance protocol should be adequately composed of TTE, including GLS, and damage markers — cTn and/or NP. In the case heart dysfunction (both asymptomatic and symptomatic), it is necessary to implement the following procedures:

1. Discontinuation/temporary interruption of treatment related to CTRCD — in contact with an oncologist, than working out a future management strategy — depending on both cancer/heart condition
2. In relation to the severity of heart dysfunction, (symptomatic/asymptomatic), heart failure treatment should be implemented (initially ACE-Inhibitors/ARBs and/or Beta-Blockers)
3. In selected patients, after achieving heart function improvement and clinical stabilization, it is possible to return to treatment related to CTRCD, under restrict surveillance — joint MDC decision [2, 3].

Practical comment

CTRCD related to the use of individual anticancer drugs has been clearly presented, it should be remembered that in many cases commonly used CTRCD related regimens contain cardiotoxic drugs administered in a combined or sequential manner.

It is very important to assess the patient before starting CTRCD treatment. In healthy patients, we can easily observe CTRCD if appeared. However, patients with initial cardiac dysfunction due to the existing dysfunction, CTRCD supervision seems more difficult.

Moreover for this group of patients the refusal of optimal cancer treatment even with potential cardiac toxicity may importantly worsens their prognosis. Therefore, the treatment of heart failure have to be optimized and if implementation anti-cancer therapy CTRCD potential is considered, it should be carefully supervised.

From a practical point of view, in the case of any heart dysfunction, even in asymptomatic patients, all available therapy should be induced based on all recommendation for the treatment of heart failure.

An increase in heart rate (HR) is a negative predictor of prognosis and quality of life, therefore HR optimization is recommended, especially in patients with sinus rhythm. The mechanisms leading to tachycardia include: sympathetic/parasympathetic imbalance related to cancer or eg. radiation therapy; factors related to cancer: stress response of the host organism to cancer,

anemia, depression, pain, reduced physical activity, etc. Appropriate HR control requires causal management and also intensive pharmacotherapy.

IMMUNE CHECKPOINT INHIBITORS (ICIS)

ICIs activate the host's immune response against tumor cells. ICIs are used extensively in a growing number of oncological indications. Among cardiac complications, serious life-threatening complications should be remembered, such as myocarditis (including fulminant), advanced heart blocks, complex ventricular arrhythmias or sudden cardiac death [5]. They most often develop within the first 12 weeks of treatment, although later cases are possible. Other adverse events include takotsubo syndrome, non-inflammatory myocardial dysfunction, vasculitis, acute coronary syndrome, and pericarditis with or without fluid.

In the event of cardiac complications, in addition to standard cardiac management, ICI should be withheld, the patient should be monitored, and in severe cases, diagnostic management should not delay high-dose steroid therapy [6]. Detailed treatment depends on the type and severity of complications, discontinuation or further continuation of treatment with ICI depends on the severity of complications and each case should be analysed by MDT optimizing the management.

Practical comment

ICIs are drugs that are increasingly used in oncological treatment, therefore it is important to keep close supervision during therapy. Strong supervision should be applied to patients receiving simultaneous combined immunotherapy (e.g. ipilimumab and nivolumab), previously subjected to other cardiotoxic therapy (e.g. VEGF tyrosine kinase inhibitors) or with a history of cardiovascular diseases (e.g. ischemic heart disease / myocardial infarction / heart failure or others). The occurrence of skeletal myositis or autoimmune disease during ICI therapy should raise vigilance. In the group of patients with current heart disease, it is absolutely necessary to optimize cardiac therapy. In patients without cardiac disease, before starting the ICI, the determination of cTn with subsequent monitoring of their concentrations during treatment it seems to be a minimum. In the group of patients with cardiological burden, strict supervision, especially at the beginning of ICI therapy, should be thorough. It is also important that a significant increase in cTn levels during ICI should be of particular concern to the cardiologist. It can be associated not only with ACS, but also with myocarditis, which can be a direct threat to the patient's life. To sum up, in ICI therapy, cardiac complications are not very common, but they can occur suddenly, directly threatening the patient's life.

ACUTE CORONARY SYNDROMES (ACS)

Patients with cancer are at increased risk of ACS due to: common risk factors, exacerbated by the pro-inflammatory/pro-thrombotic state related to cancer and CRT-CVT. The diagnosis of ACS in cancer patients does not differ significantly from other patients. They consist of i.e. clinical symptoms, ECG and serial determination of cTN (in non-ST segment elevation acute coronary syndrome (NSTE-ACS) [14]. At high CV risk, treated with CRT-CVD therapy (accelerated atherosclerosis/plaque rupture; vasospasm; thrombosis) the diagnostic vigilance should be increased, as the clinical presentation can be atypical due to cancer or cancer related side effects/therapy/frailty. Management of ACS in patients with cancer is not significantly different compared to patients without cancer (invasive management is preferred in high-risk patients with ST-segment elevation myocardial infarction (STEMI) and non-ST segment elevation myocardial infarction (NSTEMI) if cancer prognosis is ≥ 6 months or if they have acute ACS complications), although more difficult due to increased frailty syndrome, increased risk of bleeding and prothrombotic risk. Thrombocytopenia modifies the use of antiplatelet drugs: platelet count $< 10\,000$ is a contraindication to the use of aspirin, $< 30\,000$ for clopidogrel, $< 50\,000$ for prasugrel and ticagrelor [15]. In low-risk (without signs or symptoms of ongoing ischaemia or haemodynamic instability) NSTE-ACS patients with poor cancer prognosis (< 6 months) or very high bleeding risk presenting with STEMI or NSTE-ACS, a conservative, non-invasive approach can be attempted.

In justified cases, fractional flow reserve (FFR) and intracoronary ultrasound (IVUS) should be used. In patients undergoing percutaneous coronary intervention (PCI), due to a potentially higher bleeding risk (especially in patients with active GI cancer), the duration of dual antiplatelet therapy (DAPT with aspirin and clopidogrel instead of newer P2Y₁₂ antagonist) should not exceed 1–3 months [16]. If vitamin K antagonists (VKAs) or non-vitamin K antagonist anticoagulants (NOACs) are required, triple therapy after PCI should be limited to 1 week. Coronary artery bypass grafting (CABG) should be reserved for patients with ACS who are not candidates for PCI and whose survival is estimated at > 1 year. A temporary interruption of cancer therapy is recommended in patients where the cancer therapy is suspected as a contributing ACS cause [17].

Practical comment

The basic principles of ACS treatment are presented in relation to the ESC guidelines for the diagnosis and treatment of STEMI and NSTE-ACS. At the same time, they draw attention to

possible complications related to the impact of the cancer itself and related drugs, especially bleeding caused by, among others, thrombocytopenia, which is common in this group of patients, therefore attention should be paid to the length of DAPT after PCI procedures. The role of MDT should be emphasized in making decisions about the method of treatment each time (also with the use of means of distance communication and image data transmission), especially in difficult, ambiguous cases, with suspected cardiotoxicity as possible cause provoking ACS, and in assessing the expected survival of the cancer patient.

CHRONIC CORONARY SYNDROMES (CCS)

Cancer patients who present new angina symptoms, especially under cancer treatments associated with an increased risk of angina should have careful clinical evaluation. Patients with symptoms should be diagnosed in accordance with the ESC guidelines and have conservative treatment and intensive modification of cardiovascular risk factors implemented. Decisions regarding revascularization procedures (PCI, CABG) in oncology patients should be carefully balanced in MDT [16, 17]. It is important that PCI procedures in cancer patients with CCS and ACS are associated with an increased risk of bleeding, re-infarction and the need for subsequent revascularization, depending on the type of cancer. Therefore, DAPT therapy should be individualized and as short as possible (1–3 months).

Practical comment

The guidelines are quite brief on the problems faced by patients with CCS. The main principles of CCS treatment are the same for all patients, regardless of comorbidities. MDT is necessary to individualize both conservative therapy and, in particular, coronary revascularization procedures depending on the type of cancer itself and cancer treatment, careful balancing of the risk of bleeding associated with anticoagulant treatment vs. the benefits that the patient may get from revascularization, assessment of the expected length of survival, or temporary discontinuation of anticancer drugs.

CARDIAC ARRHYTHMIAS

The most important from the clinical point of view are: atrial fibrillation and ventricular arrhythmias, or rather — the potential threat of malignant ventricular tachyarrhythmias (cardiac/oncological disease and oncological treatment). Arrhythmias most often manifest themselves in advanced forms of both diseases, or as a side effect of anticancer treatment [18].

Atrial fibrillation (AF) is the most common arrhythmia in cancer patients. Due to the overlapping risk of thromboembolic complications — the presence of cancer with its treatment and the specificity of arrhythmias, early determination of anticoagulant management in this group of patients is very important. The CHA₂DS₂-VASc scale does not include cancer patients, therefore the decision threshold for anticoagulant treatment in oncological patients should be significantly reduced [19]. Anticoagulant management in patients with cancer should be individualized, in the absence of contraindications, in a long-term anticoagulant strategy, preference should be given to NOAC, with an assessment of the risk of bleeding complications.

Practical comment

There are few reports on EBM antiarrhythmic and anticoagulant management in oncological patients. The assessment of CHA₂DS₂-VASc has not been sufficiently validated in cancer patients. Chronic anticoagulant therapy is recommended in patients with AF and cancer for the prevention of ischemic stroke/other thromboembolic complications, in line with current general guidelines for the treatment of AF. Anticoagulant therapy should be considered in patients with appropriately lower CHA₂DS₂-VASc scores; chronic anticoagulation may be considered even in patients without thromboembolic risk factors (except 1 point for females) after prior assessment of bleeding risk.

The risk of serious **ventricular arrhythmias** in cancer patients is increased [20] which is associated with the use of drugs that can prolong the QTc interval. The occurrence of malignant ventricular arrhythmias or an absolute prolongation of the QTc interval >500 ms requires at least temporary discontinuation of treatment if the cancer therapy is suspected as a contributing QTc prolongation.

Practical comment

The occurrence of ventricular arrhythmias in the vast majority of cases is associated with the iatrogenic effect of cancer therapy, less often with the inflammatory/infiltrative process. Statistically, the risk of TdP is associated with an increase in the QTc interval ≥ 500 msec. Non-modifiable factors associated with VA risk include: age, sex, history of coronary/structural heart disease, and baseline QTc prolongation. Discontinuation of anti-cancer therapy and ECG monitoring is recommended in patients who result in a QTc interval ≥ 500 msec. Evaluation/correction of electrolyte disturbances is always necessary. An ECG is recommended with each increase in the dose of a drug that may prolong the QTc interval. In

antiarrhythmic prophylaxis, beta-blockers are the preferred group. It should be remembered that most antiarrhythmic drugs (including amiodarone) can prolong the QTc interval. Long-term prognosis in some oncological patients is significantly improved, therefore in the case of a high risk of malignant ventricular arrhythmias, the use of an implantable cardioverter defibrillator may be justified.

BRADYCARDIA. IMPLANTATION OF CARDIAC IMPLANTABLE ELECTRONIC DEVICES (CIEDs)

Oncology therapy-induced bradycardia is the most common after immunotherapy and immunomodulatory treatment (Table 1) [21, 22].

Practice commentary

The indications for implantation of cardiac implantable electronic devices (CIEDs) do not differ from those in the non-cancer patient population. The stage of cancer should not affect treatment decisions with CIEDs. This does not apply to the terminal stages of the disease, where a decision has been made for palliative therapy to make life more comfortable.

Cancer patients have an increased perioperative risk (bleeding and systemic infections). This is due to leukopenia, anemia, thrombocytopenia and increased susceptibility to infection.

The choice of implanted device should be dictated by the patient's ability to undergo magnetic resonance imaging [23, 24].

To reduce hematomas or infections, it is worth considering modern medical devices: electrodeless pacemakers and fully subcutaneous defibrillators.

Implantable CIED devices and radiation therapy

The use of RT in patients with CIEDs can cause irreversible damage to the device. The risk of an adverse RT/CIED interaction is increased by the cumulative dose per device (>2 Gy for a pacemaker >1 Gy for a cardioverter defibrillator (ICD) and the beam energy (>10 MV). Ignorance of the implications of the effect of RT on CIEDs puts patients at risk of disqualification from RT or misclassification of patients for removal/relocation of existing CIEDs before RT [25].

Risk stratification should be performed by the attending cardiologist/electrophysiologist and should be based on: CIED location (thoracic vs. external), cumulative dose per CIED and/or beam energy, and the presence of pacemaker dependence or frequent ICD therapies.

1. Any patient with CIED undergoing RT should have an interrogation and full device check just before starting (if the last CIED check was > 3 months after starting RT) and up to two weeks after finishing RT. Whether and how often a CIED check should be performed during RT depends on the baseline risk assessment (every week of RT for high-risk patients, no check during RT for low-risk patients).

2. High-risk patients should be monitored with ECG and pulse oximetry during each RT session. An external pacing kit should also be available.

Device extraction/relocation may occur if the CIED prevents effective RT of the tumor and/or the CIED is directly in the delivered radiation beam and the risk of damage to the CIED is very high. Such decisions should be made on a case-by-case basis taking into account the risk/benefit balance, patient age, pacemaker dependency, prognosis, type of RT (palliative vs. radical), risk of CIED infection (e.g., immunosuppressive therapy), and possibility of dose/energy reduction of RT [26, 27].

Practical comment

The guidelines do not explicitly address whether the recommendations formulated apply to other implantable devices such as arrhythmia recorders (ILRs, implantable loop recorders), leadless pacemakers (LPs, leadless pacemakers), cardiac contractility modulation (CCM) systems, subcutaneous ICDs (S-ICDs, subcutaneous ICDs), or phrenic nerve stimulators. This is probably due to the lack of data coming from clinical trials. The qualification, and care during and after RT of patients with implanted one of the above-mentioned devices should take place in centers with extensive experience in caring for CIED patients treated with RT.

Pulmonary embolism thrombosis and anticoagulant treatment

As part of venous thromboembolism (VTE) prophylaxis during oncologic treatment, patients undergoing major open or laparoscopic abdominal surgery who have a low risk of bleeding and a high risk of VTE are recommended for prolonged prophylaxis with low molecular weight heparin (LMWH) for 4 weeks after surgery (28). Prophylactic administration of LMWH for primary prevention of VTE is indicated in hospitalized patients with cancer, as well as in cases of prolonged immobilization, if there is no bleeding or other contraindications.

The recommendations highlight the possibility of using apixaban, edoxaban, or rivaroxaban to treat symptomatic or incidentally detected VTE in cancer patients. For the treatment of symptomatic or incidentally detected VTE in patients with cancer and a platelet count >50 000/ μ l, LMWH is recommended. However, when the platelet count is 25 000–5 000/ μ l,

anticoagulation with half a dose of LMWH can be considered. In patients with cancer and catheter-related VTE, anticoagulation treatment should be continued for at least 3 months, continuing longer if the catheter remains in situ.

Practical comment

Venous thromboembolism is the second most common cause of death in patients with cancer. The presence of cancer is associated with a 5-fold increase in the risk of VTE, and cancer-related VTE accounts for 30% of all VTE cases [29, 30]. Unprovoked VTE may be the first clinical manifestation of malignant neoplasm, and the rate of cancer diagnosis in the following 12 months is 5%.

Risk factors for VTE in patients with cancer are related to both the patient's clinical characteristics (older age, comorbidities, female gender, inherited coagulation disorders, functional status/ability of the patient, history of VTE), the tumor (type, genetic characteristics (JAK2 or KRAS gene mutations,) histological type (adenocarcinoma), initial period after diagnosis, primary focus (pancreas, stomach, ovary, brain, lung, myeloma), stage of disease (advanced, metastatic) as well as treatment (oncology, central venous catheters, surgery and hospitalization itself) [29].

Patients with plasmacytic myeloma have an increased risk of thrombosis. Risk factors for VTE in these patients are: patient-related — previous VTE, acute infections, autoimmune diseases, central venous catheter, chronic kidney disease, smoking, CVD, diabetes, general surgery, history of hereditary thrombophilia, immobilization, surgery, trauma, obesity (BMI >30 kg/m²); and myeloma-related: advanced disease, erythropoiesis-stimulating drugs, high-dose dexamethasone, treatment with thalidomide, lenalidomide or ponalidomide. Recommendations related to VTE prophylaxis during plasmacytic myeloma treatment include: therapeutic doses of LMWH after VTE and prophylactic doses of LMWH, at least during the first 6 months of treatment, in patients with risk factors for VTE (excluding prior VTE).

In acute pulmonary artery embolism, we follow the 2019 ESC guidelines and the second ESC expert position statement on the diagnosis and treatment of acute DVT incidentally detected proximal DVT or PE should be treated the same as symptomatic VTE, as the recurrence rate and risk of death are similar. The minimum duration of anticoagulant treatment is 6 months, and prolonged anticoagulant treatment is suggested in cases of active cancer, metastatic disease, or the use of chemotherapy.

Pregnant women

Improvements in cancer treatment in recent years have led to an increase in the number of women who become pregnant after anticancer treatment. Most have a history of exposure to radio- and chemotherapy, particularly anthracyclines, which increase the risk of cardiovascular complications. The 2022 ESC guidelines recommend cardiovascular evaluation before pregnancy or during the first trimester [1]. Such an evaluation includes at a minimum, subject and physical examination, ECG, assessment of natriuretic peptide levels and performance of cardiac ECHO. Follow-up is worth considering in patients at high cardiovascular risk who have received cardiotoxic chemotherapy.

A separate issue is when cancer is diagnosed during pregnancy (1:1 000 pregnancies) [30]. A cardiac evaluation with regular follow-up every 4-8 weeks or every 2 cycles of anthracycline drug infusion is recommended before the initiation of such oncological treatment. Cyclic evaluation of left ventricular ejection fraction and determination of natriuretic peptide concentrations are used to monitor drug cardiotoxicity. Pregnant women with cancer have a higher risk of VTE. Low-molecular-weight heparins are preferred for treatment and prophylaxis.

Practical comment

The main risk factors that are associated with the occurrence of cardiovascular incidents in pregnant women with a history of cured cancer, i.e. young age of cancer diagnosis, longer period from the start of anticancer treatment to the first pregnancy, cardiovascular complications developed during treatment, and the cumulative dose of anthracyclines used.

Breast cancer, melanoma, and cervical cancer are most commonly diagnosed in pregnancy. Echocardiographic evaluation plays an important role. An increase in stroke volume, heart rate, preload and total peripheral resistance are typical hemodynamic changes in pregnant women, resulting in an 80-85% increase in cardiac output by the end of pregnancy. Left ventricular mass and volume increase, as well as right ventricular volume. The EF value of the left ventricle, which is a parameter for monitoring cardiotoxicity, remains unchanged. Keep in mind the higher cutoff points of NTproBNP (<300 pg/mL) and BNP (<100 pg/ml) standards in pregnancy [31]. Measurement of high-sensitivity troponin, as a parameter for monitoring myocardial damage, may be considered before and during anthracycline therapy in a pregnant woman with cancer [32, 33].

Arterial hypertension

Arterial hypertension (AH) in a patient with cancer may result from:

- older age;
- anticancer drugs used: VEGFi, BCR-ABL second- and third-generation TKIs, birganitib, ibrutinib, fluoropyrimidines, cisplatin, abirsterone, bicalutamide, enzalutamide);
- glucocorticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs);
- stress, pain.

Drugs that inhibit the angiotensin renin system (ACEI/ARB) are recommended as the mainstay of hypotensive therapy in oncology patients. Combination treatment of ACEI/ARB with a dihydropyridine calcium antagonist is recommended for patients with cancer and systolic blood pressure ≥ 160 and/or diastolic blood pressure ≥ 100 mm Hg. Patients with BP values ≥ 180 and/or ≥ 110 mm Hg should have their oncology therapy causing AH temporarily stopped.

Additional medications if indicated:

- spironolactone, nitrates in transdermal preparations and/or dihydralazine in patients with refractory NT associated with cancer therapy;
- beta-blockers in patients with sympathetic nervous system activation due to stress and/or pain complaints;
- diuretics (preference for spironolactone) in patients with fluid retention.

Practical comment

The recommendations are quite conservative concerning the intensity of treatment (combination therapy only in NT stage 2) — this is in contrast to current guidelines, which favor starting therapy with combination therapy as early as $\geq 140/90$ mm Hg [34, 35].

The document's omission of thiazide/thiazide-like diuretics and preference for spironolactone as a diuretic is incomprehensible [36].

The guidelines indicate the possibility of using the following in the treatment of refractory AH: dihydralazine and nitrates in transdermal form - both groups of drugs are not available in Poland. They also mention the vasodilator beta-blockers carvedilol and nebivolol. However, highly cardioselective beta-blockers such as bisoprolol are preferred [37,38].

PULMONARY HYPERTENSION

Pulmonary arterial hypertension (TNP) (group 1) can be caused by the toxic effects of anticancer drugs on small pulmonary arterioles. The best-documented effect is that of the tyrosine kinase inhibitor (TKI) dasatinib [39, 40]. Other drugs include carfilzomib, bosutinib,

ponatinib, and interferon alfa. Alkylating agents such as cyclophosphamide and mitomycin C can lead to the development of pulmonary venous obliterative disease (PVOD). Pulmonary hypertension associated with left heart failure (group 2) is most often caused by damage to the left ventricular muscle during anticancer therapy, such as anthracyclines. Pulmonary hypertension dependent on lung damage or hypoxia (group 3) occurs in lung cancers and metastatic tumors occupying a large volume of lung tissue or after surgical resection of the lung. Anticancer therapies such as bleomycin or thoracic radiotherapy can lead to lung fibrosis and give NP by this mechanism. Active cancer is a risk factor for the development of thromboembolic pulmonary hypertension (Group 4). Central catheters and vascular ports can also be a source of recurrent embolism. The diagnostic and treatment management of an oncology patient with NP is not significantly different from that of patients without cancer.

Practical comment

From a practical point of view, prompt diagnosis for pulmonary embolism appears to be the most important, as it is an acute disease requiring immediate initiation of anticoagulant therapy. Oncology patients may require consultation of the acute pulmonary embolism response team (PERT), due to the numerous contraindications to thrombolytic therapy [41]. For dasatinib-induced NP, the drug should be discontinued, and another TKI should be used. For NP of thromboembolic etiology in patients with a history of oncology, the preferred forms of treatment are riociguat pharmacotherapy and balloon pulmonary angioplasty [42, 43].

PERICARDIAL DISEASES

The most common cause of pericardial fluid is cancer of the lung, breast, ovary, esophagus, as well as leukemia and lymphoma [44]. Both cancer drugs and radiation therapy can cause pericardial disease. Progression of cancer can be pericardial infiltration, pericardial metastasis or disruption of lymph flow from the heart. The pericardium can also be the site of primary cardiac tumors (sarcomas, lipoma, lymphomas, endothelioma) [45].

Pericarditis may be the first sign of cancer. Standard treatment is nonsteroidal anti-inflammatory drugs (e.g., ibuprofen) and colchicine for about three months. In refractory cases, steroids should be used. Pericardial effusions of low to moderate severity (4–20 mm) can be treated conservatively under echocardiographic guidance. Cardiac tamponade requires urgent pericardial puncture. In case of recurrent pericardial fluid or if puncture is not possible, surgical treatment (creation of a pericardial window) should be considered. Intrapericardial administration of drugs (cytostatics) may also be considered [46].

Pericarditis associated with ICI immunomodulatory drugs has a worse prognosis and may co-occur with myocarditis. Hence, the need for expanded diagnosis with CT and/or MRI and biomarkers is emphasized. High doses of methylprednisolone and colchicine and withholding ICI are recommended. A refractory course may be an indication for immunosuppressive therapy. A benign course allows for continued treatment with ICI along with anti-inflammatory drugs.

Practical comment

Pericarditis can occur even years after radiation therapy, and its risk increases in proportion to the radiation dose. Modern anticancer drugs, especially ICI (ipilimumab), can cause pericarditis associated with a 20% mortality rate, while others (nivolumab, atezolizumab, durvalumab, avelumab, cemiplimab) carry a mortality rate of up to 50% for myocarditis. Patients receiving ICI should have cyclic echocardiography.

ANTIPLATELET AND ANTICOAGULANT TREATMENT IN THE CARDIO-ONCOLOGY PATIENT

The oncology population is more likely to require anticoagulant treatment than the general population. The strategy of antiplatelet treatment especially in the oncology patient forces an analysis of the risk of bleeding and thrombotic complications [47, 48]. The authors of the guidelines recommend:

1. antiplatelet treatment with clopidogrel as the P2Y₁₂ inhibitor as the drug of choice.
2. NOACs should be considered in patients with atrial fibrillation for stroke prophylaxis instead of LMWH and VKAs (excluding patients with mechanical heart valves or moderate to severe mitral stenosis) in patients without a high risk of bleeding, significant drug interactions, or severe renal impairment LMWH should be considered in patients with active cancer and atrial fibrillation in whom NOACs cannot be used.
- 3 Apixaban, edoxaban, or rivaroxaban are recommended for the treatment of symptomatic or incident thromboembolism (VTE) in patients with cancer without contraindications. LMWHs are recommended for the treatment of symptomatic or incident VTE in cancer patients with platelet counts <50 000/ μ l

Practical comment

1. The preferred dual antiplatelet therapy (DAPT) drugs are acetylsalicylic acid and clopidogrel. Clopidogrel among other P2Y₁₂ inhibitors is the drug of choice. The duration of DAPT therapy should be as short as possible (1–3 months) [48].

Antiplatelet drugs should be withheld: for acetylsalicylic acid if the platelet count is below 10,000/ μ L, and for clopidogrel below 30 000/ μ L. An invasive PCI strategy can be considered if the platelet count is above 30 000/ μ L. If the platelet count is less than 20,000/ μ L and coronary angiography is necessary, platelet transfusions are recommended before the angiography procedure and a lower dose of heparin (30–50 U/kg) is used.

2. The use of VKAs in the oncology patient remains the only option in patients with atrial fibrillation and moderate to severe mitral stenosis or with a mechanical heart valve.

In most oncology patients, LMWH is a short-term anticoagulation option. It is the treatment of choice in patients with inoperable gastric/colorectal cancer, concomitant gastric disease, severe renal impairment (eGFR by CrCl <15 ml/min), interactions between ingested drugs and NOACs, and platelet counts <50 000/ μ L. For eGFR <15 ml/min, it may be necessary to dose LMWH under anti-Xa or switch to VKA [49].

3 NOACs have been evaluated as a potential alternative to LMWH for cancer-related VTE based on randomized trials (HOKUSAI, SELECT-D, CARAVAGGIO) comparing edoxaban, rivaroxaban or apixaban with dalteparin [70, 71]. NOACs are no worse than dalteparin in reducing the risk of recurrent VTE with a similar risk of major bleeding. However, a higher risk of clinically significant non-serious bleeding was observed, especially in patients with luminal gastrointestinal and genitourinary malignancies (SELECT-D trial with rivaroxaban). Edoxaban, rivaroxaban, and apixaban are recommended for the treatment of VTE (DVT and PE) in cancer patients without the following bleeding risk factors: unoperated gastrointestinal or genitourinary malignancies, recent history of bleeding or within 7 days of major surgery, significant thrombocytopenia (platelet count, 50 000/ μ L), severe renal impairment (creatinine clearance CrCl, 15 ml/min), or gastrointestinal-related comorbidities [50, 51].

CHEMOTHERAPY (ANTHRACYCLINES, 5-FU AND OTHERS). OTHER ANTICANCER DRUGS

Recommendations to reduce the cardiovascular risk during chemotherapy indicate the need for a cardiological consultation in patients at high or very high risk of cardiovascular disease before starting oncological treatment and cardiological care during anticancer therapy. Cardiac ultrasound is also recommended in all patients before starting anthracycline therapy and one year after treatment.

Practical comment

Anthracyclines are commonly used in oncology as the basis of systemic treatment of many cancers, including breast cancer, sarcomas and lymphomas, while fluoropyrimidines are the basis of treatment of gastrointestinal cancers. These drugs have a proven effect on prolonging survival in cancer patients, but often balancing the undoubted benefit and risk of their use is difficult. Appropriate and common cooperation with cardio-oncologist is important, which is not easy due to the limited number of these specialists.

BRAF AND MEK INHIBITORS — RECOMMENDATIONS FOR REDUCING CARDIOVASCULAR RISK DUE TO IBRAF AND/OR IMEK

According to the recommendations, blood pressure monitoring is indicated at each clinical visit and weekly during the first 3 months of treatment, then monthly, and in patients treated with cobimetinib/vemurafenib, ECG is also recommended after 2 and 4 weeks from the start of treatment, and every 3 months thereafter. Echocardiography is recommended in all high- and very high-risk patients prior to initiating BRAF/MEK inhibitor combination therapy and may be considered in low- to moderate-risk patients prior to initiating BRAF/MEK inhibitor combination therapy.

Practical comment

The MAPK pathway in cardiomyocytes is a protective signaling pathway, and its inhibition interferes with the mechanisms of intramyocyte repair by inhibiting extracellular signal-regulated kinases 1/2, therefore cardiac complications may occur during therapy with BRAF inhibitors and MEK inhibitors (iBRAF/iMEK). The recommendations do not include the assessment of cardiovascular risk in patients with serious cardiovascular diseases before iBRAF/iMEK therapy. Patients receiving previous oncological treatment also deserve special attention. Asymptomatic cardiotoxicity after immunotherapy or radiotherapy-induced myocardial damage may increase the risk of significant left ventricular systolic dysfunction or even heart failure during iBRAF and iMEK treatment.

QT interval prolongation may also occur during iBRAF therapy. The presented recommendations of the European Society of Cardiology indicate the need to perform ECG only during therapy with vemurafenib and cobimetinib, but there is no mention of the need to perform ECG before and during therapy with other BRAF inhibitors, such as dabrafenib or

encorafenib. It seems important to note that ECG should be performed before and during therapy with any BRAF inhibitor, not only vemurafenib.

iBRAF/iMEK treatment is associated with a significant risk of cardiac damage, including heart failure, cancer therapy-related cardiac dysfunction (HF/cardiomyopathy/CTRCD), therefore it is recommended that left ventricular ejection fraction be assessed prior to initiating iBRAF and iMEK therapy hearts. The recommendations of the European Society of Cardiology do not indicate the need to determine the level of troponins and B-type natriuretic peptide (NT-proBNP, N-terminal fragment of B-type natriuretic peptide) in blood serum before or during iBRAF/iMEK therapy. It seems, however, that in patients with serious cardiovascular diseases and at significant cardiovascular risk, especially in the case of qualification for adjuvant treatment, these tests may be considered.

Combination therapy with a BRAF inhibitor and an MEK inhibitor is associated with an increased risk of VTE compared to BRAF inhibitor monotherapy. Pulmonary embolism has been reported in 1% to 2% of patients treated with iBRAF/iMEK, which should be taken into consideration during iBRAF/iMEK therapy. Other follow-up examinations during iBRAF and iMEK therapy should be scheduled based on risk factors, clinical symptoms, and laboratory findings [1, 52].

CHECKPOINT INHIBITORS (ICIs). IMMUNOTHERAPY CAR-T — GENETICALLY MODIFIED T LYMPHOCYTES. HEMATOPOIETIC CELL TRANSPLANTATION

Immune checkpoint inhibitors (ICIs) are drugs that use the activation of the host's immune response against cancer cells as their mechanism of action. Among the cardiac complications, one should remember about serious, directly life-threatening complications, such as myocarditis (including fulminant myocarditis), advanced heart blocks, complex ventricular arrhythmias or sudden cardiac death. These severe complications, associated with high mortality, most commonly develop within the first 12 weeks of treatment, although late cardiac toxicity (after 20 weeks) is also possible.

In the case of cardiac complications, in addition to typical cardiac procedures, oncological treatment should be stopped, the patient should be monitored, and diagnostic procedures should be immediate. Concomitant treatment with steroids (in life-threatening cases methylprednisolone — bolus 500–1000 mg intravenously once daily for the first 3–5 days) in high doses should not be delayed while waiting for the results of diagnostic tests. The method of treatment depends on the type and severity of complications, and interruption or continuation

of treatment with ICIs depends on the severity of complications. Each case should be analyzed by MDT optimizing the procedure.

Practical comment

In ICIs therapy, it is important to remember to conduct cardiac monitoring, especially at the beginning of therapy. It should be emphasized that special checks are carried out on patients receiving simultaneous combined immunotherapy (e.g. ipilimumab and nivolumab), previously subjected to other cardiotoxic therapy (e.g. tyrosine kinase inhibitors, VEGF) or with a history of cardiovascular diseases (e.g. ischemic heart disease / myocardial infarction heart disease/heart failure or others). The occurrence of skeletal myositis or a history of autoimmune disease (e.g. systemic lupus erythematosus, RA, sarcoidosis or others) during ICIs therapy should be noted. In the group of patients with current heart disease, it is absolutely necessary to optimize cardiac therapy and achieve clinical stability. Before starting ICIs in the group of patients without cardiac diseases, it seems to be an absolute minimum to determine the troponin level followed by monitoring during ICIs treatment. In the group of patients with cardiac diseases, cardiological supervision should be more frequent at the beginning of ICIs therapy. On the other hand, it should be remembered that, especially during ICIs, a significant increase in troponin concentration requires further diagnostics. In addition to coronary syndrome, an increase in troponin may be associated with myocarditis.

In patients treated with immunotherapy, cardiac toxicity may occur in the form of myocarditis, pericarditis, conduction abnormalities and develop within only a few weeks of starting treatment with immune checkpoint inhibitors [53–55].

CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH PROSTATE CANCER DURING HORMONE THERAPY

The recommendations indicate the need to assess the baseline risk of cardiovascular complications and to estimate the 10-year risk of life-threatening and non-life-threatening cardiovascular complications using the SCORE2 or SCORE-OP scales in patients undergoing hormone therapy with no history of cardiovascular disease. In addition, it is recommended to perform baseline and periodic ECG examinations in patients who are at risk of prolongation of the corrected QT interval (QTc) during hormone therapy. Due to the fact that the use of GnRH (gonadotropin-releasing hormone) antagonists is associated with a significantly lower risk of death and cardiovascular complications compared to GnRH agonists, it is suggested to use

GnRH antagonists in patients with existing cardiovascular diseases -vascular patients who require hormone therapy. It is also recommended to annually assess the risk of cardiovascular complications in patients with prostate cancer during hormone therapy.

Practical comment

About 40% of prostate cancer patients are treated with hormone therapy. The most commonly used drugs are GnRH agonists, which increase the risk of cardiovascular complications and death, especially in the group of men >60 years of age. Therefore, a very important suggestion is the use of drugs from the group of GnRH antagonists (instead of GnRH agonists) in those patients with coexisting cardiovascular diseases.

It seems that the use by physicians ordering hormone therapy (clinical oncologists, radiotherapists, urologists) in outpatient settings of the extensive scales SCORE2 or SCORE-OP (4-page algorithm) developed by cardiologists is not possible in clinical practice. These scales are based on numerous clinical and laboratory parameters: gender, age, smoking, blood pressure, non-HDL cholesterol. Few oncology or urology centers have the ability to determine non-HDL-cholesterol. In addition, it should be emphasized that these scales can only be used in patients without any cardiovascular disease, diabetes, or chronic kidney disease. They are not used in patients after strokes, percutaneous revascularizations, coronary artery plasty, etc. And prostate cancer patients are mostly elderly patients with numerous comorbidities, including cardiovascular diseases. Therefore, it seems that the baseline assessment of the risk of cardiovascular complications and the estimation of the 10-year risk of life-threatening and non-life-threatening cardiovascular complications, as well as the annual assessment of these complications should be performed by a cardiologist.

It should be emphasized that all hormone therapy drugs in patients with prostate cancer can lead to QTc prolongation, but it is rare. However, QTc prolongation increases the risk of sudden death. Prostate cancer patients treated with hormone therapy may simultaneously take other drugs leading to prolongation of this segment, e.g. amiodarone, sotalol or psychotropic drugs. Therefore, during hormone therapy, it is worth monitoring this parameter (by ordering an ECG with QTc assessment) and when it is prolonged, the patient should be referred for a cardiological consultation in order to modify the dose of cardiological drugs or replace them.

CARDIOVASCULAR COMPLICATIONS IN BREAST CANCER PATIENTS TREATED WITH ANTI-HER2, CDK4/6 INHIBITORS AND/OR HORMONE THERAPY

The recommendations indicate the need to perform left ventricular ejection fraction and global systolic fraction tests before starting anti-HER2 treatment and every three months during it. In patients who have completed treatment, echoradiography should be performed 12 months after the end of treatment. In palliative patients, the assessment of cardiac function should be performed every 3 months during the first year of treatment. In the absence of cardiac symptoms suggestive of increasing damage to the myocardial function, control examinations may be performed every 6 months. In breast cancer patients previously treated with anthracycline-containing systemic regimens, it is recommended that troponin (cTn) levels be determined prior to initiation of anti-HER2 therapy. The detection of elevated cTn levels may allow to identify patients at high risk of developing heart function damage in the course of anticancer therapy with anti-HER2 drugs. However, in patients requiring systemic therapies in combination with anti-HER2 treatment, anthracycline-free regimens should always be considered. In addition, if anthracycline-based regimens and anti-HER2 therapy are necessary, sequential use of these therapies is recommended, as such treatment has been shown to significantly reduce the incidence of cardiac dysfunction in the course of anticancer therapies.

Practical comment

Referring to the recommendations regarding modern therapies used in the treatment of breast cancer, it can be stated that they focus mainly, despite the use of the term "anti-HER2 therapies", on patients receiving trastuzumab in the perioperative treatment or in the treatment of disseminated disease. There is no direct reference to the validity and scope of cardiological assessment in patients receiving therapies based on anti-HER2 antibodies combined with cytostatics (e.g. trastuzumab-emtansine, trastuzumab-deruxstecan, etc.). These recommendations also do not contain a provision relating to anti-HER2 therapies based on small-molecule kinase inhibitors that block the function of the intracellular domain of the receptor (e.g. lapatinib, tucatinib, etc.). It would be extremely important to include a recommendation regarding the risk of cardiovascular complications in the course of the use of this group of drugs and appropriate cardiological management. Cardiac management does not differ from that recommended in the case of antibodies blocking the extracellular domain of the receptor, however, from the oncologist's point of view, such data should be included. The therapeutic area of breast cancer not described in the ESC recommendations is the use of antibodies blocking a receptor other than HER2, most of which are conjugated with a cytostatic (sacituzumab govitekan and others). Perhaps it would be worth referring to this group of new therapies in Polish recommendations. In addition, the question remains whether a patient

receiving anti-HER2 therapy in the next line of treatment for disseminated disease after previous therapies blocking the HER2 receptor should be monitored in the same way as patients receiving first-line treatment for disseminated disease.

It should be remembered, however, that in Poland, anti-HER2 therapies are prescribed as part of a drug program specifying a specific method of monitoring complications of the treatment. Therefore, in the event of discrepancies between the cardiological recommendations and the drug program regarding the monitoring of cardiovascular complications, there should be a clear provision informing about the superiority of the drug program. It would be optimal to achieve consistency between the ESC guidelines and the drug program.

Recommendations for the diagnosis and monitoring of cardiovascular complications in breast cancer patients treated with hormonal therapy are based on the extensive SCORE2 and SCORE2-OP scales assessing a number of clinical and laboratory parameters. With the current number of patients admitted to the oncology office every day, it is impossible to conduct an accurate assessment based on the above scales. In addition, patients were treated for disseminated disease, receiving hormone therapy in the next line of treatment, were exposed to drugs with potentially cardiotoxic effects during previous therapies, or received a number of drugs indicated for organ dysfunction in the course of the neoplastic process. What cardiac surveillance should be applied to these patients. Is it really safe to extend the intervals between individual assessments?

Analyzing all the above doubts, it seems advisable to create guidelines for cardiological care of oncological patients at every stage of treatment.

ANTI-ALK TYROSINE KINASE INHIBITORS AND EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS

The recommendations of the European Society of Cardiology regarding treatment with a tyrosine kinase inhibitor directed against the ALK protein (anaplastic lymphoma tyrosine kinase) indicate the assessment of cardiac risk before treatment, which includes: physical examination, blood pressure measurement, ECG, lipid profile and measurement of glycated hemoglobin HbA1c.

Practical comment

Treatment with ALK inhibitors

Recommendation of cardio-oncological management before starting treatment based on ALK inhibitors and monitoring of safety during treatment introduces the need for additional

examinations before and during therapy. Currently, we have the option of using crizotinib, alectinib, ceritinib, brigatinib and lorlatinib. In terms of examinations, before inclusion in treatment, we are obliged to conduct a physical examination, an integral part of which is the measurement of heart rate and blood pressure, as well as electrocardiography. The current recommendations of the European Society of Cardiology recommend the determination of the lipid profile and the level of glycated hemoglobin as part of the initial cardiac risk assessment. So far, it has not been necessary to perform these two tests in everyday clinical practice. In the clinical trials that were the basis for the registration of crizotinib, alectinib, ceritinib, brigatinib and lorlatinib, and in post-registration studies, hyperglycemia and diabetes were not listed as significant side effects of the treatment [3, 55–62]. Therefore, the need to determine glycated hemoglobin (HbA1c) in all patients starting treatment is not justified in the summary of product characteristics and published registration works. The test may be justified in selected clinical situations (glucose intolerance, diabetes). Also, determination of the lipid profile in patients before starting treatment with all ALK kinase inhibitors is not justified by the incidence of lipid disorders. Assessment of the lipid profile and its monitoring is justified in the case of lorlatinib, in the case of which this complication is very common. In the registration study, hypercholesterolemia occurred in 70% of patients and hypertriglyceridemia in 64%, while in the case of crizotinib, the frequency of lipid metabolism disorders was low and amounted to 4% for hypercholesterolemia and 6% for hypertriglyceridemia [59]. Analyzing the above data, it is reasonable to perform a lipid profile before starting treatment and to monitor it during treatment every 3-6 months only for lorlatinib. Due to the low incidence of lipid disorders in the case of crizotinib, monitoring of lipid disorders and assessment of the lipid profile before starting treatment seems to be unjustified in everyday clinical practice [59]. Due to the high prevalence of hypertension with brigatinib (23%, including 10% in grade 3) and lorlatinib (18%, including 10% in grade 3), constant blood pressure monitoring should be performed [57, 59]. A side effect of treatment with ALK kinase inhibitors was symptomatic bradycardia with a heart rate below 50/min. Therefore, heart rate control is necessary during treatment with ALK kinase inhibitors [60].

TREATMENT WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS

Also in the case of epidermal growth factor receptor inhibitors, as part of the initial cardiac risk assessment, testing of the lipid profile and the level of glycated hemoglobin should be performed. In the clinical trials that were the basis for the registration of EGFR kinase

inhibitors, hyperglycemia and diabetes were not listed as significant side effects of the treatment [62–67]. Therefore, the need to test glycosylated hemoglobin (HbA1c) in all patients starting treatment is not justified in the summary of product characteristics and published registration papers. Also, testing the lipid profile of patients before starting treatment is not justified in the prevalence of lipid disorders. On the other hand, the recommendation to perform echocardiography before and during osimertinib treatment is related to the observed decrease in left ventricular stroke volume below 10 percentage points from baseline to an absolute value of 50% and below in 3.1% and 5.5% of patients in the FLAURA and AURA3 studies [62–64]. Most events were asymptomatic and resolved without treatment of the event or discontinuation of osimertinib. Patients with poorly controlled hypertension and later in life have an increased risk of myocardial insufficiency [66]. Based on the above data, it is reasonable to perform an echocardiographic examination before and during the treatment with osimertinib.

BCR-ABL INHIBITORS, BRUTON KINASE INHIBITORS, MULTIPLE MYELOMA DRUGS

Recommendations regarding the reduction of cardiovascular risk due to BCR-ABL inhibitors indicate the assessment of baseline cardiovascular risk in patients requiring therapy with second or third generation BCR-ABL tyrosine kinases. In patients treated with nilotinib or ponatinib, it is recommended to assess the cardiovascular risk every 3 months in the first year, and then every 6–12 months, while the measurement of the QTc interval should be considered before the start of therapy, then in the 2nd and 4th week of treatment with nilotinib, and 2 weeks after any dose increase. Echocardiography should be considered in all patients before starting treatment with second- and third-generation BCR-ABL tyrosine kinases. Echocardiography is recommended in all patients before starting dasatinib therapy. In high and very high risk patients receiving dasatinib or ponatinib, echocardiography every 3 months for the first year should be considered. Echocardiography may be considered every 6–12 months in patients requiring long-term (>12 months) therapy with ponatinib or dasatinib. Assessment of the ankle-brachial index may be considered to detect subclinical peripheral vascular disease.

Practical comment

In the treatment of multiple myeloma, multi-drug regimens are mainly used, which include, among others, glucocorticosteroids, which significantly increase the risk of hypertension. For this reason, it is advisable to systematically control blood pressure during each medical visit,

as well as self-monitoring by the patient with daily measurement and filling in a measurement diary.

Among the drugs used in multiple myeloma, special attention should be paid to the potential risk of cardiotoxicity of proteasome inhibitors (bortezomib, ixazomib, carfilzomib). Proteasomes, protein complexes responsible for the degradation of dysfunctional or unnecessary proteins, perform an important stabilizing function in cardiomyocytes, and if this function is impaired, myocardial dysfunction can occur. The greatest risk of cardiotoxicity is seen with carfilzomib. The incidence of myocardial dysfunction during treatment with bortezomib is relatively low (up to 4%) compared to carfilzomib, although the toxicity of bortezomib may be increased by concomitant use of steroids. Carfilzomib is a more potent and irreversible proteasome inhibitor with a much higher risk of myocardial damage (up to 25%). Another challenge in patients diagnosed with multiple myeloma is the high risk of thromboembolic complications resulting from the disease itself (hyperviscosity, renal failure, light chain disease) or treatment (polychemotherapy, high doses of dexamethasone, use of immunomodulatory drugs such as thalidomide, lenalidomide, pomalidomide, use of recombinant erythropoietin). Based on the analysis of risk factors, the European Myeloma Network guidelines recommend 100 mg/day aspirin for thrombosis prophylaxis in patients with one or two risk factors, and low molecular weight heparin or full-dose warfarin in patients with three or more risk factors.

Treatment with thalidomide, lenalidomide or pomalidomide significantly increases the incidence of thrombotic complications. The risk of thrombosis is lowest when the patient receives only an immunomodulatory drug, while it increases up to 3–5 times in the case of combination therapy or high doses of dexamethasone. Randomized studies have shown that the risk of thrombotic complications was lower in patients treated with bortezomib and immunomodulatory drugs compared to the group treated without a proteasome inhibitor. In addition, the combined use of thalidomide, aspirin, and warfarin was found to be comparable to low molecular weight heparin in the prevention of thrombosis in myeloma patients, except in older patients where warfarin was less effective than low molecular weight heparin.

Low molecular weight heparin remains the drug of choice in the treatment of thromboembolic complications in patients with multiple myeloma.

In the case of light chain (AL) amyloidosis, in approximately 80% of patients, amyloid deposits in the myocardium, which leads to restrictive heart failure, in which the normal left ventricular ejection fraction persists until the late stages of the disease, despite the presence of severe clinical symptoms. Cardiac involvement is diagnosed on the basis of imaging tests (ECHO,

MRI of the heart) and biochemical tests (assessment of troponin T or I and NT-proBNP concentrations. Resting ECG is also helpful in the diagnosis - some patients have low QRS complex voltage.

RECOMMENDATIONS OF THE EUROPEAN SOCIETY OF CARDIOLOGY ON THE ASSESSMENT OF CARDIOVASCULAR RISK ASSOCIATED WITH RADIOTHERAPY IN CANCER PATIENTS

The guidelines recommend the baseline assessment of cardiovascular risk and the estimation of the 10-year risk of cardiovascular disease, including fatal cardiovascular disease, using the SCORE2 or SCORE2-OP scale. Non-invasive screening for coronary artery disease should be considered in asymptomatic patients who have received >15 Gy mean cardiac dose (MHD), 5 years after completion of radiotherapy and every 5–10 years thereafter. Carotid ultrasound examination should be considered in asymptomatic patients after radiotherapy of the head/neck region, 5 years after the end of radiotherapy, and every 5–10 years thereafter. Renal artery ultrasonography should be considered in patients after radiotherapy to the abdominal and pelvic regions who have worsening renal function and/or hypertension.

Practical comment

The assessment of the incidence of cardiovascular diseases associated with radiotherapy (RT) is very difficult to determine. This is mainly due to the long time from exposure to the onset of clinical symptoms in the cardiovascular system, the concomitant use of cardiotoxic systemic therapy, the constant progress in radiotherapy techniques, changes in the treated population, and physicians not linking emerging cardiovascular diseases with previous radiation therapy. For the same reasons, it is very difficult to clearly identify possible cardiovascular diseases that are the result of radiotherapy. Radiation damage to the heart can manifest itself as pericarditis, pericardial fibrosis, diffuse myocardial fibrosis, and finally coronary artery disease (CAD), but none of these changes is specific to radiation and can occur for a variety of reasons. It should also be noted that radiotherapy usually does not cause direct damage to myocytes because they are highly differentiated and quite resistant to radiation. Radiation-induced heart failure is primarily due to myocyte ischemia, which is caused by the destruction of capillaries. Coronary atherosclerosis develops slowly over several to several dozen years, while capillary damage occurs within a few months of irradiation. It seems, therefore, that the increased incidence of myocardial infarctions after radiotherapy results from the accelerated development of atherosclerosis (normally associated with age, but here it causes illness in

younger people), and the increased number of deaths as a result of myocardial infarctions is a consequence of reduced myocardial tolerance to acute ischemia due to the already existing radiation-induced chronic ischemia of myocytes. The evolution may be rapid, with acute coronary syndrome or sudden death as the first manifestation of the disease, but more often the disease remains asymptomatic for a long time [26, 76, 77].

It is essential to identify patients with pre-existing CAD and other cardiovascular disease (CVD) prior to initiating cancer treatment. Available data indicate that pre-existing CAD significantly increases the risk of developing CAD associated with oncological treatment, therefore it is important to determine the patient's condition before starting radiotherapy. There is typically a long latency period after radiotherapy, during which CAD is asymptomatic, and symptoms may occur up to 10 years after the original therapy. New evidence suggests that adults exposed to high cumulative doses of anthracyclines and/or undergoing radiotherapy targeted at the chest should be offered lifelong surveillance. It should also be noted that there is an increasing number of patients who underwent oncological treatment in childhood, and the risk of severe CVD in this group is increased by as much as 8 times, which means that in the long-term follow-up, heart disease is one of the most common causes of death in people with who underwent oncological treatment in childhood. Cardiotoxicity of cancer treatment in childhood is most often associated with the use of anthracyclines and radiotherapy. Lifetime follow-up is recommended for patients who have received anticancer therapy in childhood and have received anthracyclines, high-dose thoracic radiotherapy, or both [26, 76, 77].

Recommendations in cardio-oncology developed under the auspices of the European Society of Cardiology is an extremely valuable and important initiative. It significantly influences the organization of diagnostic activities aimed at early detection of cardiovascular complications in the course of using modern anti-cancer therapies. These recommendations clearly emphasize the creation of Multidisciplinary Therapeutic Teams providing direct care at every stage of anti-cancer treatment. These teams, which include not only oncologists, radiotherapists or surgeons, but also, depending on the needs, cardiologists, gastroenterologists and endocrinologists, play a key role in the proper selection, in the context of comorbidities, therapeutic options and monitoring of complications of the treatment. Regardless of the formulation of the provisions of individual recommendations, it is extremely important to promote cardiologists' further specialization in the field of cardio-oncology, which is all the more important in the context of the constantly increasing number of cancer cases and the introduction of new drugs based on the latest achievements in molecular biology and clinical immunology.

References

1. Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). *Eur Heart J*. 2022; 43(41): 4229–4361, doi: [10.1093/eurheartj/ehac244](https://doi.org/10.1093/eurheartj/ehac244), indexed in Pubmed: [36017568](https://pubmed.ncbi.nlm.nih.gov/36017568/).
2. Anker MS, Sanz AP, Zamorano JL, et al. Advanced cancer is also a heart failure syndrome: a hypothesis. *Eur J Heart Fail*. 2021; 23(1): 140–144, doi: [10.1002/ejhf.2071](https://doi.org/10.1002/ejhf.2071), indexed in Pubmed: [33247608](https://pubmed.ncbi.nlm.nih.gov/33247608/).
3. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J*. 2021; 42(34): 3227–3337, doi: [10.1093/eurheartj/ehab484](https://doi.org/10.1093/eurheartj/ehab484), indexed in Pubmed: [34458905](https://pubmed.ncbi.nlm.nih.gov/34458905/).
4. Pudil R, Mueller C, Čelutkienė J, et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. *Eur J Heart Fail*. 2020; 22(11): 1966–1983, doi: [10.1002/ejhf.2017](https://doi.org/10.1002/ejhf.2017), indexed in Pubmed: [33006257](https://pubmed.ncbi.nlm.nih.gov/33006257/).
5. Čelutkienė J, Pudil R, López-Fernández T, et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). *Eur J Heart Fail*. 2020; 22(9): 1504–1524, doi: [10.1002/ejhf.1957](https://doi.org/10.1002/ejhf.1957), indexed in Pubmed: [32621569](https://pubmed.ncbi.nlm.nih.gov/32621569/).
6. Martín-García A, López-Fernández T, Mitroi C, et al. Effectiveness of sacubitril-valsartan in cancer patients with heart failure. *ESC Heart Fail*. 2020; 7(2): 763–767, doi: [10.1002/ehf2.12627](https://doi.org/10.1002/ehf2.12627), indexed in Pubmed: [32022485](https://pubmed.ncbi.nlm.nih.gov/32022485/).
7. Szmit S, Grela-Wojewoda A, Talerczyk M, et al. Predictors of new-onset heart failure and overall survival in metastatic breast cancer patients treated with liposomal doxorubicin. *Sci Rep*. 2020; 10(1): 18481, doi: [10.1038/s41598-020-75614-4](https://doi.org/10.1038/s41598-020-75614-4), indexed in Pubmed: [33116159](https://pubmed.ncbi.nlm.nih.gov/33116159/).
8. Wilk M, Waško-Grabowska A, Skoneczna I, et al. Angiotensin system inhibitors may improve outcomes of patients with castration-resistant prostate cancer during abiraterone acetate treatment—a cardio-oncology study. *Front Oncol*. 2021; 11: 664741, doi: [10.3389/fonc.2021.664741](https://doi.org/10.3389/fonc.2021.664741), indexed in Pubmed: [33869068](https://pubmed.ncbi.nlm.nih.gov/33869068/).

9. Barrett-Lee PJ, Dixon JM, Farrell C, et al. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. *Ann Oncol.* 2009; 20(5): 816–827, doi: [10.1093/annonc/mdn728](https://doi.org/10.1093/annonc/mdn728), indexed in Pubmed: [19153118](https://pubmed.ncbi.nlm.nih.gov/19153118/).
10. Dixon SB, Howell CR, Lu L, et al. Cardiac biomarkers and association with subsequent cardiomyopathy and mortality among adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort. *Cancer.* 2021; 127(3): 458–466, doi: [10.1002/cncr.33292](https://doi.org/10.1002/cncr.33292), indexed in Pubmed: [33108003](https://pubmed.ncbi.nlm.nih.gov/33108003/).
11. Tromp J, Boerman LM, Sama IE, et al. Long-term survivors of early breast cancer treated with chemotherapy are characterized by a pro-inflammatory biomarker profile compared to matched controls. *Eur J Heart Fail.* 2020; 22(7): 1239–1246, doi: [10.1002/ejhf.1758](https://doi.org/10.1002/ejhf.1758), indexed in Pubmed: [32078215](https://pubmed.ncbi.nlm.nih.gov/32078215/).
12. Cao Z, Xu C, Yang H, et al. The role of healthy lifestyle in cancer incidence and temporal transitions to cardiometabolic disease. *JACC CardioOncol.* 2021; 3(5): 663–674, doi: [10.1016/j.jacc.2021.09.016](https://doi.org/10.1016/j.jacc.2021.09.016), indexed in Pubmed: [34988474](https://pubmed.ncbi.nlm.nih.gov/34988474/).
13. Nolan MT, Marwick TH, Plana JC, et al. Effect of traditional heart failure risk factors on myocardial dysfunction in adult survivors of childhood cancer. *JACC Cardiovasc Imaging.* 2018; 11(8): 1202–1203, doi: [10.1016/j.jcmg.2017.12.011](https://doi.org/10.1016/j.jcmg.2017.12.011), indexed in Pubmed: [29454779](https://pubmed.ncbi.nlm.nih.gov/29454779/).
14. Ibanez B, James SK, Ibanez B, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J.* 2018; 39(2): 119–177, doi: [10.1093/eurheartj/ehx393](https://doi.org/10.1093/eurheartj/ehx393), indexed in Pubmed: [28886621](https://pubmed.ncbi.nlm.nih.gov/28886621/).
15. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J.* 2021; 42(14): 1289–1367, doi: [10.1093/eurheartj/ehaa575](https://doi.org/10.1093/eurheartj/ehaa575), indexed in Pubmed: [32860058](https://pubmed.ncbi.nlm.nih.gov/32860058/).
16. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with eacts. *Eur Heart J.* 2018; 39(3): 213–260, doi: [10.1093/eurheartj/ehx419](https://doi.org/10.1093/eurheartj/ehx419), indexed in Pubmed: [28886622](https://pubmed.ncbi.nlm.nih.gov/28886622/).
17. Saraste A, Knuuti J, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J.* 2020; 41(3): 407–477, doi: [10.1093/eurheartj/ehz425](https://doi.org/10.1093/eurheartj/ehz425), indexed in Pubmed: [31504439](https://pubmed.ncbi.nlm.nih.gov/31504439/).

18. Yun JP, Choi EK, Han KD, et al. Risk of atrial fibrillation according to cancer type: a nationwide population-based study. *JACC CardioOncol.* 2021; 3(2): 221–232, doi: [10.1016/j.jacc.2021.03.006](https://doi.org/10.1016/j.jacc.2021.03.006), indexed in Pubmed: [34396327](https://pubmed.ncbi.nlm.nih.gov/34396327/).
19. Chen ST, Hellkamp AS, Becker RC, et al. Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF. *Eur Heart J Qual Care Clin Outcomes.* 2019; 5(2): 145–152, doi: [10.1093/ehjqcco/qcy040](https://doi.org/10.1093/ehjqcco/qcy040), indexed in Pubmed: [30219887](https://pubmed.ncbi.nlm.nih.gov/30219887/).
20. Enriquez A, Biagi J, Redfearn D, et al. Increased incidence of ventricular arrhythmias in patients with advanced cancer and implantable cardioverter-defibrillators. *JACC Clin Electrophysiol.* 2017; 3(1): 50–56, doi: [10.1016/j.jacep.2016.03.001](https://doi.org/10.1016/j.jacep.2016.03.001), indexed in Pubmed: [29759695](https://pubmed.ncbi.nlm.nih.gov/29759695/).
21. Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. *Europace.* 2022; 24(1): 71–164, doi: [10.1093/europace/euab232](https://doi.org/10.1093/europace/euab232), indexed in Pubmed: [34455427](https://pubmed.ncbi.nlm.nih.gov/34455427/).
22. Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. *Eur Heart J.* 2022; 43(40): 3997–4126, doi: [10.1093/eurheartj/ehac262](https://doi.org/10.1093/eurheartj/ehac262), indexed in Pubmed: [36017572](https://pubmed.ncbi.nlm.nih.gov/36017572/).
23. Kusumoto FM, Schoenfeld MH, Wilkoff BL, et al. 2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction. *Heart Rhythm.* 2017; 14(12): e503–e551, doi: [10.1016/j.hrthm.2017.09.001](https://doi.org/10.1016/j.hrthm.2017.09.001), indexed in Pubmed: [28919379](https://pubmed.ncbi.nlm.nih.gov/28919379/).
24. Indik JH, Gimbel JR, Abe H, et al. 2017 HRS expert consensus statement on magnetic resonance imaging and radiation exposure in patients with cardiovascular implantable electronic devices. *Heart Rhythm.* 2017; 14(7): e97–e153, doi: [10.1016/j.hrthm.2017.04.025](https://doi.org/10.1016/j.hrthm.2017.04.025), indexed in Pubmed: [28502708](https://pubmed.ncbi.nlm.nih.gov/28502708/).
25. Tajstra M, Blamek S, Niedziela JT, et al. Patients with cardiac implantable electronic devices undergoing radiotherapy in Poland. Expert opinion of the Heart Rhythm Section of the Polish Cardiac Society and the Polish Society of Radiation Oncology. *Kardiol Pol.* 2019; 77(11): 1106–1116, doi: [10.33963/KP.15063](https://doi.org/10.33963/KP.15063), indexed in Pubmed: [31741466](https://pubmed.ncbi.nlm.nih.gov/31741466/).
26. Zamorano JL, Lancellotti P, Muñoz DR, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC

- Committee for Practice Guidelines [article in Polish]. *Kardiol Pol.* 2016; 74(11): 1193–1233, doi: [10.5603/KP.2016.0156](https://doi.org/10.5603/KP.2016.0156), indexed in Pubmed: [27910076](https://pubmed.ncbi.nlm.nih.gov/27910076/).
27. Niedziela JT, Blamek S, Gadula-Gacek E, et al. Radiation therapy in patients with cardiac implantable electronic devices. *Kardiol Pol.* 2021; 79(2): 156–160, doi: [10.33963/KP.15705](https://doi.org/10.33963/KP.15705), indexed in Pubmed: [33293501](https://pubmed.ncbi.nlm.nih.gov/33293501/).
 28. Puurunen MK, Gona PN, Larson MG, et al. Epidemiology of venous thromboembolism in the Framingham Heart Study. *Thromb Res.* 2016; 145: 27–33, doi: [10.1016/j.thromres.2016.06.033](https://doi.org/10.1016/j.thromres.2016.06.033), indexed in Pubmed: [27442716](https://pubmed.ncbi.nlm.nih.gov/27442716/).
 29. Mulder FI, Carrier M, van Doormaal F, et al. Risk scores for occult cancer in patients with unprovoked venous thromboembolism: Results from an individual patient data meta-analysis. *J Thromb Haemost.* 2020; 18(10): 2622–2628, doi: [10.1111/jth.15001](https://doi.org/10.1111/jth.15001), indexed in Pubmed: [32654348](https://pubmed.ncbi.nlm.nih.gov/32654348/).
 30. Mehta LS, Warnes CA, Bradley E, et al. Cardiovascular considerations in caring for pregnant patients: a scientific statement from the American Heart Association. *Circulation.* 2020; 141(23): e884–e903, doi: [10.1161/CIR.0000000000000772](https://doi.org/10.1161/CIR.0000000000000772), indexed in Pubmed: [32362133](https://pubmed.ncbi.nlm.nih.gov/32362133/).
 31. Tanous D, Siu SC, Mason J, et al. B-type natriuretic peptide in pregnant women with heart disease. *J Am Coll Cardiol.* 2010; 56(15): 1247–1253, doi: [10.1016/j.jacc.2010.02.076](https://doi.org/10.1016/j.jacc.2010.02.076), indexed in Pubmed: [20883932](https://pubmed.ncbi.nlm.nih.gov/20883932/).
 32. Sultan AA, West J, Tata LJ, et al. Risk of first venous thromboembolism in pregnant women in hospital: population based cohort study from England. *BMJ.* 2013; 347: f6099, doi: [10.1136/bmj.f6099](https://doi.org/10.1136/bmj.f6099), indexed in Pubmed: [24201164](https://pubmed.ncbi.nlm.nih.gov/24201164/).
 33. Hase EA, Barros VI, Igai AM, et al. Risk assessment of venous thromboembolism and thromboprophylaxis in pregnant women hospitalized with cancer: Preliminary results from a risk score. *Clinics (Sao Paulo).* 2018; 73: e368, doi: [10.6061/clinics/2018/e368](https://doi.org/10.6061/clinics/2018/e368), indexed in Pubmed: [30365820](https://pubmed.ncbi.nlm.nih.gov/30365820/).
 34. Tykarski A, Filipiak K, Januszewicz A, et al. 2019 guidelines for the management of hypertension — part 1–7. *Arterial Hypertension.* 2019; 23(2): 41–87, doi: [10.5603/ah.a2019.0008](https://doi.org/10.5603/ah.a2019.0008).
 35. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *J Hypertens.* 2018; 36(10): 1953–2041, doi: [10.1097/hjh.0000000000001940](https://doi.org/10.1097/hjh.0000000000001940), indexed in Pubmed: [30234752](https://pubmed.ncbi.nlm.nih.gov/30234752/).

36. Rajzer M, Doroszko A, Filipiak KJ, et al. Nadciśnienie tętnicze w wieku podeszłym — izolowane nadciśnienie skurczowe. Stanowisko Polskiego Towarzystwa Nadciśnienia Tętniczego [article in Polish]. *Nadciśnienie Tętnicze w Praktyce*. 2022; 8(4): 161–181.
37. Doroszko A, Dobrowolski P, Prejbisz A, et al. Nebiwołol i bisoprolol w terapii nadciśnienia tętniczego i chorób towarzyszących — konsensus ekspertów. *Nadciśnienie Tętnicze w Praktyce*. 2022; 8(1): 1–16.
38. Ostrowska A, Prejbisz A, Dobrowolski P, et al. Short and long-term survival in patients hospitalized due to COVID-19 in relation to cardiovascular risk factors and established cardiovascular diseases: the Cor-Cardio Study. *Pol Arch Intern Med*. 2023: 16441, doi: [10.20452/pamw.16441](https://doi.org/10.20452/pamw.16441), indexed in Pubmed: [36826715](https://pubmed.ncbi.nlm.nih.gov/36826715/).
39. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Heart J*. 2022; 43(38): 3618–3731, doi: [10.1093/eurheartj/ehac237](https://doi.org/10.1093/eurheartj/ehac237), indexed in Pubmed: [36017548](https://pubmed.ncbi.nlm.nih.gov/36017548/).
40. Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. *Circulation*. 2012; 125(17): 2128–2137, doi: [10.1161/CIRCULATIONAHA.111.079921](https://doi.org/10.1161/CIRCULATIONAHA.111.079921), indexed in Pubmed: [22451584](https://pubmed.ncbi.nlm.nih.gov/22451584/).
41. Pietrasik A, Gąsecka A, Kurzyna P, et al. Cancer associated thrombosis: comparison of characteristics, treatment, and outcomes in oncological and non-oncological patients followed by Pulmonary Embolism Response Team. *Pol Arch Intern Med*. 2023 [Epub ahead of print]: 16421, doi: [10.20452/pamw.16421](https://doi.org/10.20452/pamw.16421), indexed in Pubmed: [36734981](https://pubmed.ncbi.nlm.nih.gov/36734981/).
42. Kurzyna M, Darocha S, Koteja A, et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. *Postepy Kardiol Interwencyjnej*. 2015; 11(1): 1–4.
43. Darocha S, Kurzyna P, Banaszekiewicz-Cyganik M, et al. An unusual case of CTEPH treated by BPA in a patient with a single lung after cancer surgery. *Pulm Circ*. 2022; 12(2): e12064, doi: [10.1002/pul2.12064](https://doi.org/10.1002/pul2.12064), indexed in Pubmed: [35795493](https://pubmed.ncbi.nlm.nih.gov/35795493/).
44. Chahine J, Shekhar S, Mahalwar G, et al. Pericardial involvement in cancer. *Am J Cardiol*. 2021; 145: 151–159, doi: [10.1016/j.amjcard.2020.12.092](https://doi.org/10.1016/j.amjcard.2020.12.092), indexed in Pubmed: [33460602](https://pubmed.ncbi.nlm.nih.gov/33460602/).
45. Zaha VG, Meijers WC, Moslehi J. Cardio-immuno-oncology. *Circulation*. 2020; 141(2): 87–89, doi: [10.1161/circulationaha.119.042276](https://doi.org/10.1161/circulationaha.119.042276), indexed in Pubmed: [31928434](https://pubmed.ncbi.nlm.nih.gov/31928434/).
46. Adler Y, Charron P, Imazio M, et al. et al.. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and

Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J*. 2015; 36(42): 2921–2964, doi: [10.1093/eurheartj/ehv318](https://doi.org/10.1093/eurheartj/ehv318), indexed in Pubmed: [26320112](https://pubmed.ncbi.nlm.nih.gov/26320112/).

47. Mohamed MO, Van Spall HGC, Kontopantelis E, et al. Effect of primary percutaneous coronary intervention on in-hospital outcomes among active cancer patients presenting with ST-elevation myocardial infarction: a propensity score matching analysis. *Eur Heart J Acute Cardiovasc Care*. 2021; 10(8): 829–839, doi: [10.1093/ehjacc/zuaa032](https://doi.org/10.1093/ehjacc/zuaa032), indexed in Pubmed: [33587752](https://pubmed.ncbi.nlm.nih.gov/33587752/).
48. Krasieński Z, Urbanek T, Undas A, et al. Guidelines on the prevention and treatment of venous thromboembolism in cancer patients treated surgically, including patients under 18 years of age. *Acta Angiol*. 2021; 27(3): 81–112, doi: [10.5603/AA.2021.0006](https://doi.org/10.5603/AA.2021.0006).
49. Klotzka A, Iwańczyk S, Ropacka-Lesiak M, et al. Anthracycline-induced microcirculation disorders: AIM PILOT Study. *Kardiol Pol*. 2023 [Epub ahead of print], doi: [10.33963/KP.a2023.0108](https://doi.org/10.33963/KP.a2023.0108), indexed in Pubmed: [37190918](https://pubmed.ncbi.nlm.nih.gov/37190918/).
50. Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). *J Clin Oncol*. 2018; 36(20): 2017–2023, doi: [10.1200/JCO.2018.78.8034](https://doi.org/10.1200/JCO.2018.78.8034), indexed in Pubmed: [29746227](https://pubmed.ncbi.nlm.nih.gov/29746227/).
51. Puślecki M, Stefaniak S, Katarzyński S, et al. AngioVac: The first in Poland percutaneous solid thrombus aspiration from the right atrium. *Kardiol Pol*. 2022; 80(1): 103–104, doi: [10.33963/KP.a2021.0128](https://doi.org/10.33963/KP.a2021.0128), indexed in Pubmed: [34643258](https://pubmed.ncbi.nlm.nih.gov/34643258/).
52. Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. *Ann Oncol*. 2020; 31(2): 171–190, doi: [10.1016/j.annonc.2019.10.023](https://doi.org/10.1016/j.annonc.2019.10.023), indexed in Pubmed: [31959335](https://pubmed.ncbi.nlm.nih.gov/31959335/).
53. Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. *JAMA Oncol*. 2018; 4(12): 1721–1728, doi: [10.1001/jamaoncol.2018.3923](https://doi.org/10.1001/jamaoncol.2018.3923), indexed in Pubmed: [30242316](https://pubmed.ncbi.nlm.nih.gov/30242316/).
54. Arangalage D, Degrauwe N, Michielin O, et al. Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors. *Cancer Treat Rev*. 2021; 100: 102282, doi: [10.1016/j.ctrv.2021.102282](https://doi.org/10.1016/j.ctrv.2021.102282), indexed in Pubmed: [34438238](https://pubmed.ncbi.nlm.nih.gov/34438238/).

55. Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. *N Engl J Med.* 2017; 377(9): 829–838, doi: [10.1056/NEJMoa1704795](https://doi.org/10.1056/NEJMoa1704795), indexed in Pubmed: [28586279](https://pubmed.ncbi.nlm.nih.gov/28586279/).
56. Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. *Lancet.* 2017; 389(10072): 917–929, doi: [10.1016/S0140-6736\(17\)30123-X](https://doi.org/10.1016/S0140-6736(17)30123-X), indexed in Pubmed: [28126333](https://pubmed.ncbi.nlm.nih.gov/28126333/).
57. Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. *N Engl J Med.* 2018; 379(21): 2027–2039, doi: [10.1056/NEJMoa1810171](https://doi.org/10.1056/NEJMoa1810171), indexed in Pubmed: [30280657](https://pubmed.ncbi.nlm.nih.gov/30280657/).
58. Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus crizotinib in advanced ALK inhibitor-naïve alk-positive non-small cell lung cancer: second interim analysis of the phase III ALTA-1L trial. *J Clin Oncol.* 2020; 38(31): 3592–3603, doi: [10.1200/jco.20.00505](https://doi.org/10.1200/jco.20.00505), indexed in Pubmed: [32780660](https://pubmed.ncbi.nlm.nih.gov/32780660/).
59. Solomon BJ, Bauer TM, Mok TSK, et al. First-line lorlatinib or crizotinib in advanced -positive lung cancer. *N Engl J Med.* 2020; 383(21): 2018–2029, doi: [10.1056/NEJMoa2027187](https://doi.org/10.1056/NEJMoa2027187), indexed in Pubmed: [33207094](https://pubmed.ncbi.nlm.nih.gov/33207094/).
60. Wang L, Wang W. Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer (Review). *Oncol Rep.* 2021; 45(1): 13–28, doi: [10.3892/or.2020.7851](https://doi.org/10.3892/or.2020.7851), indexed in Pubmed: [33200229](https://pubmed.ncbi.nlm.nih.gov/33200229/).
61. Omar NE, Fahmy Soliman AI, Eshra M, et al. Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS). *ESMO Open.* 2021; 6(6): 100315, doi: [10.1016/j.esmoop.2021.100315](https://doi.org/10.1016/j.esmoop.2021.100315), indexed in Pubmed: [34864500](https://pubmed.ncbi.nlm.nih.gov/34864500/).
62. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. *N Engl J Med.* 2018; 378(2): 113–125, doi: [10.1056/NEJMoa1713137](https://doi.org/10.1056/NEJMoa1713137), indexed in Pubmed: [29151359](https://pubmed.ncbi.nlm.nih.gov/29151359/).
63. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. *N Engl J Med.* 2020; 382(1): 41–50, doi: [10.1056/nejmoa1913662](https://doi.org/10.1056/nejmoa1913662), indexed in Pubmed: [31751012](https://pubmed.ncbi.nlm.nih.gov/31751012/).
64. Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. *N Engl J Med.* 2017; 376(7): 629–640, doi: [10.1056/NEJMoa1612674](https://doi.org/10.1056/NEJMoa1612674), indexed in Pubmed: [27959700](https://pubmed.ncbi.nlm.nih.gov/27959700/).

65. Ewer MS, Tekumalla SH, Walding A, et al. Cardiac safety of osimertinib: a review of data. *J Clin Oncol*. 2021; 39(4): 328–337, doi: [10.1200/JCO.20.01171](https://doi.org/10.1200/JCO.20.01171), indexed in Pubmed: [33356419](https://pubmed.ncbi.nlm.nih.gov/33356419/).
66. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol*. 2012; 13(3): 239–246, doi: [10.1016/S1470-2045\(11\)70393-X](https://doi.org/10.1016/S1470-2045(11)70393-X), indexed in Pubmed: [22285168](https://pubmed.ncbi.nlm.nih.gov/22285168/).
67. Sequist LV, Yang JCH, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. *J Clin Oncol*. 2013; 31(27): 3327–3334, doi: [10.1200/jco.2012.44.2806](https://doi.org/10.1200/jco.2012.44.2806), indexed in Pubmed: [23816960](https://pubmed.ncbi.nlm.nih.gov/23816960/).
68. Broccoli A, Argnani L, Morigi A, et al. Long-term efficacy and safety of ibrutinib in the treatment of CLL patients: a real life experience. *J Clin Med*. 2021; 10(24): 5845, doi: [10.3390/jcm10245845](https://doi.org/10.3390/jcm10245845), indexed in Pubmed: [34945141](https://pubmed.ncbi.nlm.nih.gov/34945141/).
69. Treon SP, Meid K, Gustine J, et al. Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with waldenström macroglobulinemia. *J Clin Oncol*. 2021; 39(6): 565–575, doi: [10.1200/JCO.20.00555](https://doi.org/10.1200/JCO.20.00555), indexed in Pubmed: [32931398](https://pubmed.ncbi.nlm.nih.gov/32931398/).
70. Christensen BW, Zaha VG, Awan FT. Cardiotoxicity of BTK inhibitors: ibrutinib and beyond. *Expert Rev Hematol*. 2022; 15(4): 321–331, doi: [10.1080/17474086.2022.2067526](https://doi.org/10.1080/17474086.2022.2067526), indexed in Pubmed: [35437106](https://pubmed.ncbi.nlm.nih.gov/35437106/).
71. Sestier M, Hillis C, Fraser G, et al. Bruton's tyrosine kinase inhibitors and cardiotoxicity: more than just atrial fibrillation. *Curr Oncol Rep*. 2021; 23(10): 113, doi: [10.1007/s11912-021-01102-1](https://doi.org/10.1007/s11912-021-01102-1), indexed in Pubmed: [34342738](https://pubmed.ncbi.nlm.nih.gov/34342738/).
72. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). *Eur Heart J*. 2016; 37(36): 2768–2801, doi: [10.1093/eurheartj/ehw211](https://doi.org/10.1093/eurheartj/ehw211), indexed in Pubmed: [27567406](https://pubmed.ncbi.nlm.nih.gov/27567406/).
73. Zangari M, Fink L, Zhan F, et al. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.

- Clin Lymphoma Myeloma Leuk. 2011; 11(2): 228–236, doi: [10.1016/j.clml.2011.03.006](https://doi.org/10.1016/j.clml.2011.03.006), indexed in Pubmed: [21575928](https://pubmed.ncbi.nlm.nih.gov/21575928/).
74. Palumbo A, Cavo M, Bringhen S, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. *J Clin Oncol*. 2011; 29(8): 986–993, doi: [10.1200/jco.2010.31.6844](https://doi.org/10.1200/jco.2010.31.6844), indexed in Pubmed: [21282540](https://pubmed.ncbi.nlm.nih.gov/21282540/).
75. Giannopoulos K et al. Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrazji plazmocytoowych na rok 2021 [text in Polish] 2021.
76. Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). *Eur Heart J*. 2022; 43(41): 4229–4361, doi: [10.1093/eurheartj/ehac244](https://doi.org/10.1093/eurheartj/ehac244), indexed in Pubmed: [36017568](https://pubmed.ncbi.nlm.nih.gov/36017568/).
77. Tajstra M, Blamek S, Niedziela JT, et al. Chorzy z implantowanym urządzeniem do elektroterapii serca poddawani radioterapii w warunkach polskich. *Kardiol Pol Zeszyty Edukacyjne*. 2019; 77(Suppl. III): 82–89.

Table 1.

Therapy	Symptoms requiring intervention	Treatment
Immunotherapy with immune checkpoint inhibitor (ICI) drugs	With and without the presence of myocarditis: 1. occurrence of new AV block I° 2. PQ interval > 300 ms	1. Monitoring with serial ecg recordings 2. Hospitalization, ECG monitoring, intravenous methylprednisolone
Immunomodulatory drugs (IMiD): thalidomide, pomalidomide; anaplastic lymphoma kinase inhibitors (ALKi <i>anaplastic lymphoma kinase inhibitors</i>): crizotinib,	Loss of consciousness, pre-fainting states, decreased exercise tolerance: Holter test (sinus inhibition, sinus bradycardia)	1. well tolerated in patients without organic heart disease 2. test withdrawal of cancer therapy to confirm the association of symptoms with therapy

alectinib, brigatinib, ceritinib		3. evaluation of the possibility of alternative therapies 4. no alternative - pacemaker implantation.
----------------------------------	--	--